Results from several encouraging studies were presented last week atthe 96th Annual Meeting of the American Urological Association in California, USA, which demonstrated the efficacy of certain drugs in the treatment of erectile dysfunction.
Lilly ICOS' Cialis
Lilly ICOS LLC, the joint venture between ICOS and Eli Lilly, has presented new data from a Phase III study which showed that 85% of men with mild-to-severe ED taking 20mg of its new phosphodiesterase-5 inhibitor Cialis (IC351) reported improved erections compared with baseline, and 78% of intercourse attempts by men taking the drug were successful. Importantly, 63% of men treated with this dose of Cialis achieved an erectile function score considered to be normal for healthy men, as measured by the International Index of Erectile Function.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze